Marinus Pharmaceuticals’ (MRNS) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $2.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. Royal Bank of Canada lowered their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a report on Friday, October 25th. Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Stock Down 1.9 %

Shares of MRNS stock traded down $0.01 during mid-day trading on Thursday, reaching $0.30. The company’s stock had a trading volume of 1,600,465 shares, compared to its average volume of 1,584,877. The company’s 50 day simple moving average is $1.24 and its 200-day simple moving average is $1.32. Marinus Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $11.26. The firm has a market capitalization of $16.71 million, a PE ratio of -0.12 and a beta of 1.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. The business had revenue of $8.54 million for the quarter, compared to the consensus estimate of $8.95 million. Marinus Pharmaceuticals had a negative net margin of 446.48% and a negative return on equity of 7,831.35%. As a group, research analysts anticipate that Marinus Pharmaceuticals will post -1.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently modified their holdings of MRNS. Point72 DIFC Ltd bought a new stake in shares of Marinus Pharmaceuticals in the second quarter worth about $28,000. SG Americas Securities LLC bought a new stake in shares of Marinus Pharmaceuticals in the second quarter worth about $34,000. AQR Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Marinus Pharmaceuticals in the second quarter worth about $64,000. Finally, Values First Advisors Inc. boosted its position in shares of Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.